Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05133518 · ClinicalTrials.gov registry record · Phase 2
A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)
A Phase 2 study of Cataract, sponsored by Melt Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 3
- Study locations
NCT05133518 is a Phase 2 study of Cataract that has completed, run by Melt Pharmaceuticals. The registered enrollment target is 338 participants, above the 224-participant average among 83 other Cataract trials with a reported enrollment target (51% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT05133518, a Phase 2 study of Cataract, has completed, sponsored by Melt Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary purpose of the study is to evaluate the efficacy and safety of MELT-300 (Midazolam and Ketamine Sublingual Tablets) and the contribution of midazolam and ketamine components to sedation and during the surgery or ocular analgesia in participants undergoing cataract surgery with lens replacement.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MELT-300
- DRUG Midazolam alone
- DRUG Ketamine alone
Study Locations (3)
California
- Martel Eye Medical Group - Rancho Cordova
Florida
- Levenson Eye Associates - Jacksonville
North Dakota
- Vance Thompson Vision - West Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2021-07-20 |
| Est. Completion | 2022-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05133518
The ClinicalTrials.gov registry entry for NCT05133518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 83 other Cataract trials with a reported enrollment target (51% higher). The listed sponsor is Melt Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05133518 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, North Dakota.
Frequently Asked Questions
What is clinical trial NCT05133518 about?
NCT05133518 is a clinical study titled "A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)". The primary purpose of the study is to evaluate the efficacy and safety of MELT-300 (Midazolam and Ketamine Sublingual Tablets) and the contribution of midazolam and ketamine components to sedation and during the surgery or ocular analgesia in participants undergoing cataract surgery with lens repla...
What is the current status of trial NCT05133518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2021-07-20. Estimated completion is 2022-11-03.
What conditions does trial NCT05133518 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT05133518?
The interventions under investigation include: Placebo (DRUG), MELT-300 (DRUG), Midazolam alone (DRUG), Ketamine alone (DRUG).
Who is sponsoring clinical trial NCT05133518?
This trial is sponsored by Melt Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05133518 being conducted?
This trial has 3 study locations across California, Florida, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.